ReviewExpert review of molecular diagnostics2015
Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.
Review in Expert review of molecular diagnostics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort study.Translational lung cancer research · 2026Article
- Daily Practice Assessment ofCancers · 2022Review
- Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).Current oncology (Toronto, Ont.) · 2022Article
- CT texture analysis for prediction of EGFR mutational status and ALK rearrangement in patients with non-small cell lung cancer.La Radiologia medica · 2021Article
- Salivary Biomarkers in Lung Cancer.Mediators of inflammation · 2021Review
- The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer.OncoTargets and therapy · 2019Article
- Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder.Scientific reports · 2018Article
- Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).International journal of oncology · 2018Review
- Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer.International journal of cancer · 2018Article
- Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA.Cancer management and research · 2018Article
- Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma.International journal of nanomedicine · 2018Article
- ctDNA and CTCs in Liquid Biopsy - Current Status and Where We Need to Progress.Computational and structural biotechnology journal · 2018Review
- Molecular characteristics and clinical outcomes ofOncotarget · 2017Article
- Article
- Emerging Role of MicroRNAs as Liquid Biopsy Biomarkers in Gastrointestinal Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Review
- Emerging technologies for salivaomics in cancer detection.Journal of cellular and molecular medicine · 2017Review
- Clinical applications of urinary cell-free DNA in cancer: current insights and promising future.American journal of cancer research · 2017Review
- The NGS and PCR-based Detection of EGFR Mutations in Liquid Biopsy: A Systematic Review and Meta-analysis Compared With Tissue Biopsy in Treatment-naïve Patients With Non-small Cell Lung Cancer.Cancer diagnosis & prognosisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Advances in target therapies for lung cancer have enabled detection of gene mutations, specifically those of EGFR. Assays largely depend on the acquisition of tumor tissue biopsy, which is invasive and may not reflect the genomic profile of the tumor at treatment due to tumor heterogeneity or changes that occur during treatment through acquired resistance. Liquid biopsy, a blood test that detects evidence of cancer cells or tumor DNA, has generated considerable interest for its ability to detect EGFR mutations. However, its clinical application is limited by complicated collection methods and the need for technique-dependent platforms. Recently, simpler techniques for EGFR mutant detection in urine or saliva samples have been developed. This review focuses on advances in liquid biopsy and discusses its potential for clinical implementation in lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.